Status:
TERMINATED
Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Lead Sponsor:
Mayo Clinic
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Prognosis for many carcinomas, including ovarian carcinoma, is dependent on a complete surgical resection, also known as a R0 resection. At present, the ability to perform a complete resection with ne...
Eligibility Criteria
Inclusion
- Women who are:
- Diagnosed with or at high clinical suspicion of primary ovarian cancer by either radiologic imaging or physical examination or biopsy or serum tumor markers
- Scheduled to undergo surgical cytoreduction via laparotomy
- At least 18 years of age
- Capable and willing to provide informed consent
Exclusion
- Women with:
- Known sarcomatous histologies
- Recurrent ovarian cancer
- Planned surgical approach via laparoscopy or robotic surgery
- A history of anaphylactic reactions to Folate-FITC or insects
- Inability or unwillingness to provide informed consent
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01511055
Start Date
January 1 2012
End Date
June 1 2014
Last Update
November 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905